Regorafenib

4-[4-({[4-Chlor-3-(trifluormethyl)phenyl]carbamoyl}amino)-3-fluorphenoxy]-N-methylpyridin-2-carboxamid-Hydrat

L01XE21

Cytostatic

Tyrosine kinase inhibitor

513.4 ° C

Slightly soluble in water

Attention

Template: Infobox chemical / molecular formula search available

Regorafenib is a tyrosine kinase inhibitor that is currently being investigated for use in various tumor types. For the treatment of colorectal cancer in the USA is an admission since 2012, in the EU since 2013.

Indication

Regorafenib is currently used for the treatment of metastatic colorectal cancer in adults when the first treatment option has not achieved the desired effect. In some countries it is also used for the treatment of gastrointestinal stromal tumor ( GIST).

Effect

Regorafenib affects antitumor and anti-angiogenesis through inhibition of different kinases ( VEGFR, TIE2, KIT, RET, RAF -1, BRAF, BRAFV600E, PDGFR, FGFR ). The new benefit assessment of the drug recently showed an average survival benefit of 1.5 months.

Side effects

Common adverse effects include weakness, fatigue, loss of appetite, decreased food intake, hand -foot syndrome, diarrhea, weight loss, infections, high blood pressure and voice disorders.

In addition Regorafenib is liver toxic. By breaking through CYP3A4 and UGT1A9 it also has a potential for various drug interactions.

Swell

  • ATC -L01
  • Health Harmful substance
  • Tyrosine kinase inhibitor
  • Fluoraromat
  • Chlorobenzene
  • Carboxamide
  • Pyridine
  • Diaryl
  • Urea
  • Anilide
CAS registry number PubChem Anatomical Therapeutic Chemical Classification System Tyrosine-kinase inhibitor
676585
de